DAP10 Activators
DAP10 activators encompass a diverse array of chemicals that intricately modulate the activity of DAP10, a transmembrane signaling adaptor protein crucial for immune cell activation. Among these activators, PP2 emerges as a notable player, acting as an indirect activator by inhibiting Src family kinases, thereby potentially impacting downstream signaling pathways involved in DAP10 activation. The intricate relationship between PP2 and DAP10 necessitates further exploration to elucidate the precise molecular mechanisms involved. U73122, a phospholipase C (PLC) inhibitor, may indirectly activate DAP10 by inhibiting PLC, potentially influencing downstream signaling cascades related to DAP10. Similarly, LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences DAP10 by inhibiting PI3K, altering downstream signaling pathways associated with DAP10 activation. These indirect activators showcase the intricate interplay between intracellular signaling components and DAP10, contributing to the modulation of DAP10 expression or activity.
Ruxolitinib, a Janus kinase (JAK) inhibitor, may indirectly activate DAP10 by inhibiting JAK and influencing downstream signaling pathways associated with DAP10 activation. NSC23766, a Rac1 inhibitor, impacts DAP10 by inhibiting Rac1, potentially affecting downstream signaling pathways involved in DAP10 activation. The complex relationship between these chemical activators and DAP10 involves intricate mechanisms, including protein-protein interactions, modulation of intracellular signaling pathways, and alterations in cellular responses. Understanding these interactions provides valuable insights into the regulation of DAP10 and its role in immune cell activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
A Janus kinase (JAK) inhibitor that may indirectly activate DAP10. Ruxolitinib inhibits JAK, potentially influencing downstream signaling pathways associated with DAP10 activation. Indirectly, Ruxolitinib may modulate DAP10 by affecting intracellular signaling cascades, potentially altering DAP10 expression or activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
An inhibitor of nuclear factor-kappa B (NF-κB) activation that indirectly influences DAP10. Bay 11-7082 inhibits NF-κB activation, potentially affecting downstream signaling pathways involved in DAP10 activation. Indirectly, Bay 11-7082 may modulate DAP10 by influencing intracellular signaling cascades, potentially altering DAP10 expression or activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A c-Jun N-terminal kinase (JNK) inhibitor that may indirectly activate DAP10. SP600125 inhibits JNK, potentially influencing downstream signaling pathways associated with DAP10 activation. Indirectly, SP600125 may modulate DAP10 by affecting intracellular signaling cascades, potentially altering DAP10 expression or activity. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
A structurally related analog of LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor that may indirectly influence DAP10. LY303511 inhibits PI3K, potentially impacting downstream signaling pathways related to DAP10 activation. Indirectly, LY303511 may modulate DAP10 by affecting intracellular signaling cascades, potentially altering DAP10 expression or activity. | ||||||
SB202190 hydrochloride | 350228-36-3 | sc-222294 sc-222294A | 1 mg 5 mg | $131.00 $505.00 | 13 | |
A p38 MAPK inhibitor that may indirectly activate DAP10. SB202190 inhibits p38 MAPK, potentially influencing downstream signaling pathways related to DAP10 activation. Indirectly, SB202190 may modulate DAP10 by affecting intracellular signaling cascades, potentially altering DAP10 expression or activity. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
A Syk inhibitor that may indirectly influence DAP10. BAY 61-3606 inhibits Syk, potentially impacting downstream signaling pathways involved in DAP10 activation. Indirectly, BAY 61-3606 may modulate DAP10 by affecting intracellular signaling cascades, potentially altering DAP10 expression or activity. | ||||||